MRUS - Merus N.V.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
15.82
-0.18 (-1.13%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close16.00
Open16.09
Bid15.73 x 900
Ask25.00 x 1000
Day's Range15.70 - 16.14
52 Week Range10.19 - 20.95
Volume18,703
Avg. Volume170,493
Market Cap459.437M
Beta (5Y Monthly)0.76
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
All
News
Press Releases
  • GlobeNewswire

    Merus to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 01, 2020 -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company”, “we”, or “our”), a clinical-stage oncology company developing.

  • GlobeNewswire

    Merus Announces the Acceptance of Six Abstracts at Upcoming Medical Conferences and Provides Program Updates

    Four abstracts regarding zenocutuzumab (“Zeno”), including results from an independent epidemiology study of the prevalence of NRG1 gene fusion-positive (“NRG1+”) cancers, will be presented at the American Society for Clinical Oncology ASCO20 Virtual Scientific Program (ASCO), May 29-31, 2020. Abstracts detailing interim data from the Phase 1 MCLA-117 acute myeloid leukemia (AML) trial and an analysis of an extensive, proprietary panel of CD3 bispecific antibodies will be presented at the 25th European Hematology Association (EHA) Annual Congress Virtual Edition, June 11-14, 2020.

  • GlobeNewswire

    Merus Announces Financial Results for the First Quarter and Provides Business Update

    MCLA-128, zenocutuzumab, Phase 1/2 eNRGy trial remains on track MCLA-117 program update to be presented at upcoming medical meeting Anand Mehra, M.D. to succeed Russell Greig,.

  • GlobeNewswire

    Merus Announces Financial Results for the Fourth Quarter and Full Year 2019 and Provides Business Update

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 12, 2020 -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, or “our”), a clinical-stage oncology company developing innovative,.

  • ImmunoPrecise Subsidiary Joins Genmab and Merus in Expansion to new Biotech Accelerator at the Center of Europe's Most Competitive Science Region
    CNW Group

    ImmunoPrecise Subsidiary Joins Genmab and Merus in Expansion to new Biotech Accelerator at the Center of Europe's Most Competitive Science Region

    VICTORIA and UTRECHT, The Netherlands , Jan. 9, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced that its wholly owned subsidiary U-Protein Express BV signed a long-term lease contract for the new multi-tenant building for life sciences "Accelerator" at the Utrecht Science Park ( Utrecht, The Netherlands ). In addition to accommodating large biotechnology companies, the new building will offer space to companies that want to accelerate their development.

  • GlobeNewswire

    Merus Announces Chief Executive Officer Transition

    — Bill Lundberg, M.D., nominated for appointment as Chief Executive Officer —— Ton Logtenberg, Ph.D., to step down after 16 years of leadership —— Transition to occur December.

  • GlobeNewswire

    Merus Announces Financial Results for the Third Quarter 2019 and Provides Business Update

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 12, 2019 -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage company developing.

  • GlobeNewswire

    Merus Announces Pricing of Public Offering of Common Shares

    Merus N.V. (MRUS), a clinical-stage bispecific antibody company developing Biclonics®, today announced the pricing of an underwritten public offering of 4,750,000 common shares, at a public offering price of $14.50 per share, before underwriting discounts and commissions. Merus also granted the underwriters a 30-day option to purchase up to an additional 712,500 common shares. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $68.9 million, excluding any exercise of the underwriters’ option to purchase additional common shares.

  • GlobeNewswire

    Merus N.V. Announces Proposed Underwritten Public Offering of Common Shares

    Merus N.V. (MRUS), a clinical-stage bispecific antibody company developing Biclonics®, today announced the launch of a proposed underwritten public offering of up to $60.0 million of its common shares. All of the common shares are being offered by Merus N.V. In addition, Merus expects to grant the underwriters a 30-day option to purchase up to an additional $9.0 million of its common shares at the public offering price, on the same terms and conditions. The offering is subject to market conditions and other closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • GlobeNewswire

    Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions

    Merus N.V. (MRUS), a clinical-stage company developing innovative, full-length bispecific antibodies (Biclonics®), today announced initial clinical data for three patients with cancers harboring NRG1 fusions treated with MCLA-128 through an Early Access Program (EAP), and provided an overall update on the MCLA-128 clinical programs. Data on the three EAP patients were presented today by study investigators at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA. Investigators from Memorial Sloan Kettering Cancer Center (MSKCC) provided a summary and initial data concerning the treatment of three cancer patients harboring NRG1 fusions with MCLA-128 at 750 mg administered intravenously every other week.  These patients’ NRG1 gene fusions were identified using RNA-based sequencing.

  • GlobeNewswire

    Merus Announces Presentation and Poster on MCLA-128 and MCLA-129 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    UTRECHT, The Netherlands and BOSTON, Oct. 25, 2019 -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage bispecific antibody company developing.

  • GlobeNewswire

    Merus Announces Financial Results for the Second Quarter 2019 and Provides Business Update

    UTRECHT, The Netherlands, Aug. 19, 2019 -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®,.